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Abstract
Background Transcatheter embolisation is widely used to
close pulmonary arteriovenous malformations (PAVMs) in
patients with hereditary haemorrhagic telangiectasia (HHT).
Data on the direct cardiovascular haemodynamic changes
induced by this treatment are scarce.
Objectives We investigated the direct haemodynamic effects
of transcatheter embolisation of PAVMs, using non-invasive
finger pressure measurements.
Methods During the procedure, blood pressure, heart rate
(HR), stroke volume (SV), cardiac output (CO), total periph-
eral resistance (TPR) and delta pressure/delta time (dP/dt)
were continuously monitored using a Finometer®. Potential
changes in these haemodynamic parameters were calculated
from the pressure registrations using Modelflow® methodol-
ogy. Absolute and relative changes were calculated and com-
pared using the paired sample t-test.
Results The present study includes 29 HHT patients (mean
age 39±15 years, 11 men) who underwent transcatheter
embolotherapy of PAVMs. The total number of embolisations
was 72 (mean per patient 2.5). Directly after PAVM closure,
SV and CO decreased significantly by −11.9 % (p=0.01) and
−9.5 % (p=0.01) respectively, without a significant change in
HR (1.8 %). Mean arterial blood pressure increased by 4.1 %
(p=0.02), while the TPR and dP/dt did not increase signifi-
cantly (5.8 % and 0.2 %, respectively).
Conclusions Significant haemodynamic changes occur di-
rectly after transcatheter embolisation of PAVMs, amongst
which a decrease in stroke volume and cardiac output are
most important.
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Introduction
Hereditary haemorrhagic telangiectasia (HHT) is an autoso-
mal dominant inherited disease characterised by vascular
malformations, ranging from small telangiectases in skin and
mucosal membranes to large visceral arteriovenous
malformations (AVMs) predominantly localised in the lungs,
brain and liver [1–3]. Pulmonary arteriovenous malformations
(PAVMs) are abnormally dilated vessels between pulmonary
arteries and veins that cause a permanent extra-cardiac right-
to-left shunt, which carries the risk of cerebral paradoxical
embolisation of both thrombotic and septic origin [2]. Trans-
catheter embolisation of PAVMs can be safely performed, in
order to prevent these potentially severe neurological compli-
cations, such as ischaemic stroke or cerebral abscess [3, 4].
Currently, there are no data regarding the potential haemody-
namic changes occurring directly after PAVM embolisation.
Therefore, the present study investigated the direct
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haemodynamic effects of PAVM embolisation, using non-
invasive finger pressure measurements.
Methods
Patient population
Between 2008 and 2010, we included 29 patients who
underwent transcatheter embolisation of PAVMs in the St.
Antonius Hospital Nieuwegein, which is a national HHT
referral centre in the Netherlands. All patients provided in-
formed consent.
Transcatheter embolotherapy of PAVMs
A PAVM was defined as a direct communication between a
pulmonary artery and a pulmonary vein, bypassing the pul-
monary capillary filter [5], and was diagnosed using transtho-
racic contrast echocardiography (TTCE) and subsequent chest
computed tomography (CT). Before and after PAVM emboli-
sation, the right-to-left shunt fraction was measured using the
100 % oxygen method as previously described [6]. All pa-
tients were discussed in a multidisciplinary team including a
pulmonologist and interventional radiologist. PAVMs with a
feeding artery diameter of 2–3 mm or greater were found
suitable for embolisation therapy [7]. The procedure
(Fig. 1a–c) was performed under local anaesthesia (lidocaine
1 %). Percutaneous access was derived through the right
femoral vein and a six French sheath was inserted.
The interventional radiologist selected the PAVM clo-
sure device, based on the diameter and anatomy of the
PAVM. The most preferred closure device was the
Amplatzer® vascular plug (AGA Medical, Golden Val-
ley, MN, USA) (Fig. 1d). Plugs with a diameter of 4–
12 mm were used. If PAVM closure with a plug was
not possible, detachable coils (Boston Scientific, Natick,
Ma) were used. The embolic material was implanted
under fluoroscopic guidance, with a maximum contrast
volume of 300 ml (Xenetix; Iobitrol, Guerbet,
Villepinte, France). Within 24 h after embolisation, a
chest X-ray was performed. No standard medication was
given.
Haemodynamic changes after PAVM embolisation, using
non-invasive finger pressure measurements
[8–10]. The hand was kept at heart level and a cuff was
wrapped around the same arm for individual blood pressure
calibration using the return-to-flow calibration [8, 11]. Be-
cause of potential distortion of the measurements at the time
of PAVM closure, parameters were recorded after stabilisation
of the finger pressure signal during a blanking period of 1 min
immediately before and after placement of the first and the last
plug.
Data registration and analysis
During the PAVM embolisation, finger pressure measure-
ments with the associated event marks were monitored and
digitally stored. Review of these data was performed using
BeatScope® software. Five minute averages of systolic
(SBP), diastolic (DBP) and mean blood pressure (MBP),
heart rate (HR), stroke volume (SV), cardiac output
(CO), total peripheral resistance (TPR) and delta
pressure/delta time (dP/dt) were calculated after an elec-
tronic calibration procedure. SV and CO (CO is the
product of SV and HR) were calculated from the finger
pressure wave using the Modelflow® methodology [12].
The cardiac index (CI) was calculated from the CO and
the body surface area. TPR was defined as MBP divid-
ed by CO [8].
Return-to-flow calibration, using the arm cuff, was used for
calibration of the blood pressure. There was no calibration
with invasive determinations for the CO, SV and TPR. Both
absolute values and absolute and relative changes (delta ab-
solute and delta percent) are presented.
Statistical analysis
The statistics were performed using SPSS version 17.0 for
Windows (SPSS Inc., Chicago, IL, USA). Descriptive statis-
tics were used to describe patient characteristics. Continuous
variables with normal distribution were presented as mean ±
SD. Differences within groups were analysed performing




A total of 29 HHT patients (62 % female, mean age 39.2±
15.3 years) were included, in which 72 PAVMswere embolised
(mean per patient 2.5). An Amplatzer® plug was used in 54
cases and a detachable coil in the remaining 18 cases. The
baseline characteristics are presented in Tables 1 and 2.
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During the transcatheter embolisation of PAVMs, arterial
pressure was measured on a finger of the left hand using a
Finometer® device (FMS, Finapres Medical Systems, Am-
sterdam, the Netherlands). The Finometer® measures blood
pressure by a combination of the volume clamp method of
Penaz and the ‘Physiocal’ criteria developed by Wesseling
Fig. 1 a Pulmonary angiogram
of pulmonary arteriovenous
malformation in the left lower
lobe. b Selective angiogram of
pulmonary arteriovenous
malformation in the left lower
lobe. c Embolisation of
pulmonary arteriovenous
malformation in the left lower
lobe with a Amplatzer® vascular
plug. d Amplatzer® vascular plug
Table 1 Baseline characteristics of patients
Total 29





HHT Definite 28 (96.6)
Type 1 19 (65.5)
Type 2 2 (6.9)
Type unknown 8 (27.6)
SaO2 (%) Before procedure 95.5±3.5
After procedure 98.4±2.3
Shunt fraction (%) Before procedure 13.6±8.3
After procedure 4.9±6.6
All characteristics are written in number of patients with percentage or
mean with standard deviation
BMI body mass index, BSA body surface area, Kg kilogram, kg/m2
kilogram per square meter, HHT hereditary haemorrhagic telangiectasia,
SaO2 saturation level of oxygen in haemoglobin, PAVM pulmonary
arteriovenous malformation
Table 2 Baseline characteristics of embolisation procedure
Treated PAVMs 1 PAVM 9 (31.0)
2 PAVMs 9 (31.0)
3 PAVMs 2 (6.9)
4 PAVMs 8 (27.6)
>4 PAVMs 1 (3.4)
Closure device Amplatzer plug 54 (75.0)
Coil 18 (25.0)
Plug diametera <4 (mm) 1 (1.9)
4 (mm) 13 (24.1)
6 (mm) 13 (24.1)
8 (mm) 9 (16.7)
10 (mm) 10 (18.5)
>10 (mm) 6 (11.1)
Not known 2 (3.7)
All characteristics are written in number with percentage
PAVM pulmonary arteriovenous malformation, mm millimetre
a Diameter coils are not know
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Haemodynamic changes using non-invasive finger pressure
measurements
Directly after PAVM embolisation the SV and CO decreased
significantly: −6.4±13.0 ml (range −45.9 to 17.9 ml; −11.9 %,
p=0.01) and −0.4±0.8 l/min (range −3.0 to 1.58 l/min; −9.5 %,
p=0.01). As expected, the CI decreased as well (range −1.5 to
0.9 l/min/m2; −9.5 %, p=0.01). DBP and MBP increased
significantly by 5.2±10.3 mmHg (range −9.0 to 32.9 mmHg;
5.9 %, p=0.01) for DBP and 5.7±12.1 mmHg (range −12.7 to
32.6 mmHg; 4.1 %, p=0.02) for MBP, respectively. There was
no significant change in SBP (4.0±16.3 mmHg (range −25.5 to
38.5 mmHg; 1.7 %, p=0.20). The dP/dt did not change signif-
icantly: 2.1±290.0 mmHg/s (range −750.0 to 848.2 mmHg/s;
0.2%, p=0.97). There was a correlation between the delta dP/dt
and the SBP (Pearson coefficient r=0.73, r2=0.53, p<0.0001).
HR and TPR increased, but this appeared to be non-significant:
1.6±7.4 beats/min (range −17.4 to 21.2 beats/min; 1.8 %, p=
0.24) and 0.1±0.5 Woods units (range −1.62 to 1.39 Woods
units; 5.8 %, p=0.16). These data are summarised in Table 3.
Discussion
To our knowledge, this is the first study describing the occur-
rence of significant haemodynamic changes directly after
transcatheter embolisation of PAVMs. Using the Finometer®
and Modelflow® methodology, our study accurately recorded
beat-to-beat non-invasive finger pressure measurements and
thereby the immediate haemodynamic changes after PAVM
embolisation, amongst which a decrease in SV and CO were
most important.
Only one case report previously documented haemody-
namic changes 4 months after PAVM embolisation with a
marked reduction in CO of −5.1 l/min (41%) [13]. This seems
to be in line with the results in our current study in 29 HHT
patients who all underwent transcatheter embolisation of
PAVMs. However, we found a less pronounced decrease in
CO, which can be explained by the smaller right-to-left shunts
in our study population, with a mean shunt fraction before
closure of 14 % versus 31 % described by Andrivet et al. [13].
It is possible that the CO may further decrease over time as a
result of additional thrombosis of the plug or coil in the PAVM
feeding artery. However, the long-term haemodynamic chang-
es after PAVM embolisation remain hard to predict, since new
PAVMs may occur and existing PAVMs may grow, so this is
still subject for larger studies in the future.
The haemodynamic responses after PAVM embolisation
may differ between HHT patients, which can be related to
difference in number and size of PAVMs at baseline [2]. In the
(HAVMs) in different HHT subtypes [5, 14, 15]. HAVMs
may cause a hyperdynamic circulation with high CO [7]. In
Table 3 Haemodynamic measurements before and after embolisation with absolute and relative changes
Before ± SD After ± SD Delta absolute Delta percent P
SBP (mmHg) 144.9±25.3 148.9±28.4 4.0 1.7 0.20
DPB (mmHg) 85.5±11.5 90.7±16.3 5.2 5.9 0.01
MBP (mmHg) 108.0±16.0 113.7±19.9 5.7 4.1 0.02
HR (beats/min) 78.8±14.6 80.4±13.9 1.6 1.8 0.24
SV (ml) 70.9±20.9 64.5±19.3 −6.4 −11.9 0.01
CO (l/min) 5.5±1.6 5.1±1.4 −0.4 −9.5 0.01
CI (l/min/m2) 3.0±0.8 2.8±0.8 −0.2 −9.5 0.01
TPR (woods units) 1.4±0.5 1.5±0.5 0.1 5.8 0.16
dP/dt (mmHg/s) 1,233.7±463.8 1,235.8±481.7 2.1 0.2 0.97
SBP systolic blood pressure, DBP diastolic blood pressure,MBP mean blood pressure, HR heart rate, SV stroke volume, CO cardiac output, CI cardiac
index, TPR total peripheral resistance, dP/dt delta pressure/delta time, SD standard deviation,minminutes, mlmillilitres, l/min litres per minute, mmHg
millimetres of mercury, s second
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present study, nine patients underwent embolisation of at least
4 PAVMs in one session, whereas less PAVMswere embolised
in the remaining 20 patients. Furthermore, a total of 16 PAVMs
were treated with a large plug (diameter ≥10 mm), whereas 14
PAVMs could be treated with smaller endovascular plugs
(diameter ≤4 mm). Unfortunately, we could not find a signif-
icant association between plug size (size of the PAVM) and the
changes in haemodynamic parameters. Furthermore, the hae-
modynamic response can be influenced by a different preva-
lence of underlying hepatic arteriovenous malformations
our cohort, only one patient had a history of HAVMs, which
might be an underestimation, since screening for HAVMs was
only performed when clinically or biochemically suspected.
Clinically significant HAVMs seemed to be absent in the
present study, as a hyperdynamic circulation with an abnormal
high CI at baseline was not documented in the present study
(mean CI within the normal range of 3.0±0.8 l/min/m2). The
amount of microscopic PAVMs under the detection limit of
chest CT may further influence the shunt percentage and
different haemodynamic responses in HHT patients.
Due to the decrease in pulmonary right-to-left shunt from 14
to 5 % after PAVM embolisation, a consequent decrease in
preload and SV can be expected (mean change −12 % in the
current study). As there was no change in HR, the CO decreased
as well (−9.5 %). The MBP increased by 4 % after PAVM
embolisation, which is probably due to the non-significant in-
crease in TPR (6 %), as the MBP is a product of TPR and CO.
As blood pressure is inversely related to indoor temperature
[16], the fall in ambient temperature during the procedure may
have caused further vasoconstriction and thereby an increase in
blood pressure. In a previous study about the association be-
tween brachial pulse dP/dt and other haemodynamic parameters
in a chronic haemodialysis population, a Pearson coefficient of
r=0.6 (r2=0.36, p<0.001) was reported for the correlation be-
tween the delta blood pressure and the delta dP/dt [17]. This is in
line with the results found in our study (r=0.73, r2=0.53,
p<0.0001) and demonstrates that the dP/dt is responsible for
more than 50 % of variance in the blood pressure. Because of
the significant increase in MBP and decrease in CO, we also
expected a significant increase in TPR. A possible explanation
might be an increase in central venous pressure due to the
embolisation. Unfortunately, no measurements of the right atri-
um pressure were performed during the embolisation procedure.
A potential clinical implication of our findings might be
associated with the presence of pulmonary hypertension (PH)
in HHT [18, 19]. PH can occur both as gene-related pulmo-
nary arterial hypertension and as a response to high output due
to HAVMs [14]. As PAVMs are abnormally dilated vessels
between pulmonary arteries and veins they provide low resis-
tance pathways for the pulmonary blood flow and one may
therefore expect an elevation in pulmonary artery pressure
(PAP) after transcatheter closure. Surprisingly, in a prior study
by Shovlin et al. there was no described increase in PAP after
transcatheter embolisation of PAVMs [14]. It was suggested
that this might be caused by other haemodynamic changes, for
example recruitment of the pulmonary vasculature or a de-
crease in CO, although this has been previously suggested in
only one case report [13]. We now present the first study that
confirms the decrease in CO after embolisation in a larger
population of HHT patients, which may indeed provide a
potential explanation for the absent increase in PAP after
embolisation. Furthermore, PAVM-related hypoxaemia can
induce pulmonary vasoconstriction with a concomitant in-
crease in pulmonary vascular resistance (PVR). In our study
there was indeed an increase in saturation after embolisation
of PAVMs (Table 1) with probably an decrease in pulmonary
vasoconstriction and PVR.
Study limitations
First, our study is limited by its small sample, which may have
influenced the results. Second, the Modelflow® model does
not seem to be accurate in measuring absolute values of SV,
CO and TPR. The differences between the uncalibrated model
and invasive determinations (measured with the
thermodilution method) in individual patients are usually
small, but can be substantial and unreliable in some [8, 20].
However, the Modelflow® methodology is an accurate model
to compare changes in haemodynamics within one patient [8]
and the British Hypertension Society has recommended the
Finometer® for measurements in the clinical set-up as well as
for research purposes [8, 21].
Conclusion
The present study shows that significant haemodynamic chang-
es occur directly after embolisation of pulmonary arteriovenous
malformations, amongst which a decrease in stroke volume and
cardiac output are most important. This may especially provide
additional insights into the haemodynamic responses after
PAVM embolisation in HHT patients prone to PH.
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